- Indications and Usage Monoammonium Glycyrrhizinate and Cysteine Hydrochloride and Sodium Chloride Injection is indicated for the treatment of acute hepatitis, chronic hepatitis, hepatitis with liver damage, and other diseases accompanied by abnormal liver function.
- Dosage and Administration Recommended Dosage: The usual dosage is 100-250 mL administered intravenously once daily. Administration: The solution must be administered via slow intravenous drip. Dose Adjustments: Dosage should be adjusted or the medication discontinued if significant electrolyte imbalances or hypertension occur during treatment.
- Mechanism of Action Monoammonium Glycyrrhizinate: Inhibits the activation of phospholipase A2, providing anti-inflammatory and hepatoprotective effects while reducing the release of transaminases. Cysteine Hydrochloride: Serves as a precursor for glutathione synthesis, enhancing the body’s antioxidant capacity and promoting detoxification.
- Safety and Warnings Hypokalemia: The drug may cause potassium excretion, leading to hypokalemia, muscle weakness, and increased blood pressure. Sodium and Fluid Retention: Sodium retention may occur, potentially exacerbating hypertension or heart failure. Contraindications: The drug is contraindicated in patients with severe hypokalemia, congestive heart failure, and renal failure.
- Adverse Reactions and Clinical Research Common Adverse Reactions: Nausea, vomiting, abdominal distension, skin itching, urticaria, headache, dizziness, palpitations, and increased blood pressure. Clinical Research: Clinical studies have demonstrated the efficacy of the drug in improving liver function indices and alleviating symptoms in patients with liver diseases.
- Drug Interactions Diuretics: Concomitant use with loop diuretics (e.g., furosemide) may intensify potassium excretion and increase the risk of hypokalemia. Antihypertensives: The drug may antagonize the effects of antihypertensive medications due to sodium retention.
- Pharmaceutical Information Composition: The active ingredients are Monoammonium Glycyrrhizinate and Cysteine Hydrochloride. The vehicle contains Sodium Chloride. Appearance: A colorless, clear liquid for intravenous infusion. Storage: Store in a tight container in a cool, dark place, protected from light and temperatures not exceeding 20°C.
Huineng Monoammonium Glycyrrhizinate and Cysteine Hydrochloride Sodium Chloride Injection
Brand Name: 回能 ®（Huineng®)
Generic Name: Monoammonium Glycyrrhizinate and Cysteine Hydrochloride Sodium Chloride
Strength: 100 mL per bottle
Manufacturer: Honghe Pharmaceutical (China) Co., Ltd.
Marketing Authorization Holder: Honghe Pharmaceutical (China) Co., Ltd.
Approval Date in China: September 13, 2005
Registration Number: 国药准字H20058905
Storage: Seal tightly, store in a cool and dark place (temperature not exceeding 20°C). Keep out of reach of children. Refer to the full package insert for detailed storage specifications.
Price&Cost:Contact Us now for the best price of Monoammonium Glycyrrhizinate and Cysteine Hydrochloride Sodium Chloride（Huineng）
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.